Sava Infond D.O.O. Biogen Inc. Transaction History
Sava Infond D.O.O.
- $566 Billion
- Q4 2024
A detailed history of Sava Infond D.O.O. transactions in Biogen Inc. stock. As of the latest transaction made, Sava Infond D.O.O. holds 1,650 shares of BIIB stock, worth $229,993. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,650Holding current value
$229,993% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding BIIB
# of Institutions
999Shares Held
130MCall Options Held
1.12MPut Options Held
1.47M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.33 Billion0.05% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$2.24 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.03 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.02 Billion0.06% of portfolio
-
Wellington Management Group LLP Boston, MA4.93MShares$687 Million0.14% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $20.1B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...